NEEDHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing…
BILLERICA, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), announced that it was suspending all distribution operations to…
Featured Image for Owkin Featured Image for OwkinNEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Owkin appointed Professor Vassili Soumelis…
Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics First-in-class peptidomimetic with distinct MoA…
– In the initial clinical data from low-dose cohort of the ongoing trial, we observed that LX1001 expressed the protective…
Cohort 4 to Enroll Patients with Non-Obstructive Hypertrophic CardiomyopathySOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated…
SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing…
Statera developing STAT-205 as novel therapy for immune modulation in treating post-acute (long-haul) patients with SARS-CoV-2 (COVID-19)FORT COLLINS, Colo., March…
NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on…
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for…